Accedere provides cybersecurity auditing and compliance services to ensure organizations meet digital security standards, while also operating a subsidiary that manufactures and sells consumer drones.
The company operates in a regulated cybersecurity niche, but financial metrics contradict any moat claim; net margins are deeply negative (-28.5%) and ROCE is negligible (2.2%), suggesting no durable competitive advantage or pricing power.
Management has pivoted from IT services to cybersecurity and now drones, using capital to fund loss-making operations and unrelated subsidiaries rather than generating shareholder returns. The recent move to re-issue forfeited shares and implement an ESOP suggests a focus on capital raising and dilution over organic value creation.
The company's pivot from cybersecurity to drones proved to be a classic case of 'diworsification,' where capital was incinerated in a sector where they possessed no edge. The lack of internal controls and independent oversight eventually led to a breakdown in financial reporting, while the high promoter concentration allowed for continued related-party transactions that drained the remaining liquidity. As revenue growth stalled, the market finally recognized that the negative margins were structural rather than transitional, leading to a permanent re-rating of the stock as a speculative shell rather than a technology leader.
RichFakir rates Accedere Ltd's business quality as mediocre — 43/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Accedere Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Accedere Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Accedere Ltd's fair value is about ₹16 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →